Ignite Creation Date:
2025-12-25 @ 12:14 AM
Ignite Modification Date:
2026-05-25 @ 2:44 PM
Study NCT ID:
NCT05421858
Status:
RECRUITING
Last Update Posted:
2025-12-19
First Post:
2022-06-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
Sponsor:
Basilea Pharmaceutica
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
FMGX-CS-301
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | FED | View |